Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-676 Microdosing in Head and Neck Cancer
NCT06062602Phase 1Completed
- Sponsor
- Presage Biosciences
- Start
- Jul 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dazostinag in head and neck squamous cell carcinoma (HNSCC), sponsored by Presage Biosciences. Primary endpoint: Quantification of Cell Death and Immune Cell Biomarkers. Started Jul 2021; status: completed.
02
Drugs
dazostinag
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06062602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06062602.